Omrix Biopharmaceuticals plans to raise $55 million in an IPO priced at $15 to $17 a share. The offering sets a midpoint valuation of the company at $229 million. The company plans to trade on NASDAQ as OMRI. If the IPO proceeds as planned, Omrix CEO Robert Taub will see his stake in the company drop from 32.1 percent to 24.4 percent.
- read the report from Globes